Erasca, Inc. (ERAS) is an innovative biopharmaceutical company, based in San Diego, California. It was founded by a team of passionate visionaries who aspire to not just treat, but eradicate cancer, hence the name – Erasca, which stands for "erase cancer”.
Armed with this ambitious goal, Erasca has been tirelessly working to develop novel therapies that come attached with the potential to address the unmet needs of cancer patients. The company concentrates its efforts on discovering, developing, and commercializing oncology drugs, with a particular focus on genetic drivers of cancer and broader drug resistance mechanisms associated with tumors.
The company was brought into existence in 2018 and since then, has been channelizing its efforts to build an extensive pipeline of potential drug candidates, strategically poised for clinical studies. The pipeline includes ERAS-007, an extracellular signal-regulated kinase (ERK1/2) inhibitor which is an oral small molecule that restricts the activity of ERK1 and ERK2, which are proteins that play crucial roles in the biological pathway that contributes to the growth and proliferation of cancer cells.
Erasca’s business model is rooted in extensive scientific research and a commitment to clinical excellence. Its progress is propelled by collaboration with a distinguished group of strategic partners who are equally committed to defeating cancer. Emphasizing rigorous clinical development, the talented team of experienced scientists, and professionals at Erasca consistently strives for new discoveries that can potentially lead to transformational therapies and cures for the different types and stages of cancer.
Equipped with cutting-edge technologies, Erasca aims to revolutionize the cancer therapeutic landscape by aiming for groundbreaking medical advancements. By adopting an aggressive strategy towards research and development and fostering collaboration with global partners, Erasca hopes to extend and improve the quality of life for patients battling cancer.
Furthermore, Erasca is committed to maintaining an ethical approach in conducting its business and operates with full transparency. The company upholds a patient-centered focus, always putting the patient’s needs and outcomes at the forefront of its operations.
In summary, Erasca is more than a pharmaceutical company – it’s an entity that is determined to bring about an end to one of humanity's most devastating diseases. As it continues to discover novel therapeutics, the company hopes to leave an indelible mark on the global cancer therapeutic landscape, effectively paving the way towards the ultimate goal of erasing cancer.